Can analysts adopt a bullish outlook for Trillium Therapeutics Inc. (NASDAQ:TRIL)?

April 17, 2018 - By Hazel Jackson

Trillium Therapeutics Inc. (NASDAQ:TRIL) Ratings Coverage

Among 2 analysts covering Trillium Therapeutics (NASDAQ:TRIL), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Trillium Therapeutics had 3 analyst reports since December 14, 2017 according to SRatingsIntel. On Friday, April 13 the stock rating was initiated by Leerink Swann with “Hold”. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, December 14. As per Monday, March 12, the company rating was maintained by H.C. Wainwright. Below is a list of Trillium Therapeutics Inc. (NASDAQ:TRIL) latest ratings and price target changes.

13/04/2018 Broker: Leerink Swann Rating: Hold New Target: $7.0000 Initiate
12/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $10.0 Maintain
14/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $10.0 Maintain

The stock decreased 0.36% or $0.025 during the last trading session, reaching $6.875. About 8,870 shares traded. Trillium Therapeutics Inc. (NASDAQ:TRIL) has risen 12.70% since April 17, 2017 and is uptrending. It has outperformed by 1.15% the S&P500.

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company has market cap of $85.72 million. The companyÂ’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. It currently has negative earnings. The Company’s product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.